Edition:
United Kingdom

Roche Holding AG (ROG.S)

ROG.S on Virt-X Level 1

240.40CHF
4:31pm BST
Change (% chg)

CHF-1.00 (-0.41%)
Prev Close
CHF241.40
Open
CHF240.60
Day's High
CHF242.10
Day's Low
CHF240.00
Volume
1,208,228
Avg. Vol
1,555,171
52-wk High
CHF273.00
52-wk Low
CHF218.30

ROG.S

Chart for ROG.S

About

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas:... (more)

Overall

Beta: 0.98
Market Cap(Mil.): CHF209,088.59
Shares Outstanding(Mil.): 862.56
Dividend: 8.20
Yield (%): 3.40

Financials

  ROG.S Industry Sector
P/E (TTM): 21.45 30.61 31.81
EPS (TTM): 11.25 -- --
ROI: 20.46 14.48 14.02
ROE: 46.88 15.57 15.34

Big city biotechs decamp for suburbs as property costs rise

NEW YORK The biotech industry is facing high rents and tight lab space in Boston, New York and San Francisco, forcing companies into the suburbs in a sign the "live, work and play" movement into big cities may have hit a roadblock.

18 Aug 2017

UPDATE 1-Big city biotechs decamp for suburbs as property costs rise

NEW YORK, Aug 18 The biotech industry is facing high rents and tight lab space in Boston, New York and San Francisco, forcing companies into the suburbs in a sign the "live, work and play" movement into big cities may have hit a roadblock.

18 Aug 2017

CORRECTED-Big city biotechs decamp for suburbs as property costs rise

NEW YORK, Aug 18 The biotech industry is facing high rents and tight lab space in Boston, New York and San Francisco, forcing companies into the suburbs in a sign the "live, work and play" movement into big cities may have hit a roadblock.

18 Aug 2017

BRIEF-Dermira enters into agreement to license exclusive, worldwide rights to Lebrikizumab

* Dermira enters into agreement to license exclusive, worldwide rights to Lebrikizumab

08 Aug 2017

BRIEF-FDA grants orphan drug designation to Kadmon's tesevatinib for the treatment of egfr-mutated non-small cell lung cancer

* FDA grants priority review and breakthrough therapy designation for zelboraf (vemurafenib) in erdheim-chester disease with braf v600 mutation

07 Aug 2017

UK finds Roche bladder cancer drug too costly for routine use

LONDON Britain's healthcare cost-effectiveness agency NICE has decided Roche's new immunotherapy drug Tecentriq is too expensive to justify its routine use to treat bladder cancer, but still hopes it can be used in certain circumstances.

02 Aug 2017

UK finds Roche bladder cancer drug too costly for routine use

LONDON Britain's healthcare cost-effectiveness agency NICE has decided Roche's new immunotherapy drug Tecentriq is too expensive to justify its routine use to treat bladder cancer, but still hopes it can be used in certain circumstances.

02 Aug 2017

UK finds Roche bladder cancer drug too costly for routine use

LONDON, Aug 2 Britain's healthcare cost-effectiveness agency NICE has decided Roche's new immunotherapy drug Tecentriq is too expensive to justify its routine use to treat bladder cancer, but still hopes it can be used in certain circumstances.

02 Aug 2017

Roche leukaemia drug gets FDA breakthrough therapy designation

ZURICH Roche Holding AG's Venclexta has won breakthrough therapy designation in acute myeloid leukaemia (AML) from the U.S. Food and Drug Administration, the Swiss drugmaker said on Friday.

28 Jul 2017

Roche leukaemia drug gets FDA breakthrough therapy designation

ZURICH, July 28 Roche Holding AG's Venclexta has won breakthrough therapy designation in acute myeloid leukaemia (AML) from the U.S. Food and Drug Administration, the Swiss drugmaker said on Friday.

28 Jul 2017

Earnings vs. Estimates